Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature [PDF]
Endocrinology and Metabolism, 2022 Denosumab, which has been approved for the treatment of osteoporosis since 2010, is a fully humanised monoclonal antibody against a cytokine, receptor activator of nuclear factor kappa B ligand (RANKL), involved in bone resorption.
Wei Lin Tay, Donovan Tay
doaj +1 more source
Tocotrienol regulates osteoclastogenesis in rheumatoid arthritis [PDF]
The Korean Journal of Internal Medicine, 2021 Background/Aims The present study aimed to investigate whether tocotrienol regulates interleukin 17 (IL-17)-induced osteoclastogenesis in rheumatoid arthritis (RA).
Kyoung-Woon Kim +6 more
doaj +1 more source
Dynamics and thermodynamics of protein-ligand interactions [PDF]
, 2012 Complex networks of protein-ligand interactions underpin cellular function and communication. Disease can arise from disruption of these networks through the alteration of protein-ligand interaction affinities, for example by protein mutation or ligand ...
Malham, Richard William
core +6 more sources
N-acetyl-l-cysteine controls osteoclastogenesis through regulating Th17 differentiation and RANKL in rheumatoid arthritis [PDF]
The Korean Journal of Internal Medicine, 2019 Background/Aims This study aimed to determine the regulatory role of N-acetyl-l-cysteine (NAC), an antioxidant, in interleukin 17 (IL-17)-induced osteoclast differentiation in rheumatoid arthritis (RA).
Hae-Rim Kim +4 more
doaj +1 more source
NIP45 negatively regulates RANK ligand induced osteoclast differentiation [PDF]
Journal of Cellular Biochemistry, 2012 Shanmugarajan S +3 more
exaly +2 more sources
The effects of chitosan oligosaccharides on OPG and RANKL expression in a rat osteoarthritis model [PDF]
Acta Cirúrgica Brasileira, 2017 Purpose: To investigate the effect of chitosan oligosaccharides (COS) against osteoarthritis (OA) and preliminarily discuss the osteoprotegerin (OPG), receptor activator of NF-κB ligand (RANKL) and RANK expression in a rat OA model.
Chun Zhang +6 more
doaj +1 more source
Breast Cancer: Rank Ligand Inhibition [PDF]
Breast Care, 2010 Breast cancer and bone health are closely linked. Early menopause induced by gonadotropin-releasing hormone analogues or chemotherapy as well as aromatase inhibitors reduce oestrogen levels, thereby causing cancer treatment-induced bone loss (CTIBL). Furthermore, bone metastases are commonly found in advanced disease. Current treatment options for bone
Rupert, Bartsch +3 more
openaire +2 more sources
Receptor activator of NF-kappaB and podocytes: towards a function of a novel receptor-ligand pair in the survival response of podocyte injury. [PDF]
PLoS ONE, 2012 BACKGROUND: Glomerulosclerosis correlates with reduction in podocyte number that occurs through mechanisms which include apoptosis. Podocyte injury or podocyte loss in the renal glomerulus has been proposed as the crucial mechanism in the development of ...
Shuangxin Liu +17 more
doaj +1 more source
Lipopolysaccharide- TLR-4 Axis regulates Osteoclastogenesis independent of RANKL/RANK signaling
BMC Immunology, 2021 Background Lipopolysaccharide (LPS) is an endotoxin and a vital component of gram-negative bacteria’s outer membrane. During gram-negative bacterial sepsis, LPS regulates osteoclast differentiation and activity, in addition to increasing inflammation ...
Mohammed S. AlQranei +4 more
doaj +1 more source
Evaluation of the effect of topical and systemic ozone application in periodontitis: an experimental study in rats [PDF]
Journal of Applied Oral Science, 2019 Objective: The goal of the present study was to determine the effect of systemic and topical ozone application on alveolar bone loss (ABL) by evaluating the effect of Hypoxia-inducible factor −1 alpha (HIF-1-α) and receptor activator of NF-kB ligand ...
Ebru Saglam +4 more
doaj +2 more sources